Laura Faez-García

Laura Faez-García

Auto-generated profile, based on publicly available information

Laura Faez-García

Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
PFPaula Jimenez Fonseca
Paula Jimenez Fonseca
MSMaria Pilar Solis-Hernandez
Maria Pilar Solis-Hernandez
MGM. Garrido
M. Garrido
LFL. Faez
L. Faez
DRD. Rodriguez
D. Rodriguez
JVJ. M. Viéitez
J. M. Viéitez
A proportion of patients with metastatic colorectal cancer (mCRC) are still able to continue with active therapy after their progression to fluoropyrimidines, oxaliplatin, and irinotecan regimens. Studies suggest that gemcitabine and fluoropyrimidines are synergic antimetabolites. The purpose was to evaluate gemcitabine–capecitabine (Gem–Cape) in heavily pretreated mCRC and to thus assess possible predictive factors for progression-free survival (PFS) and overall survival (OS).

20 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMaria Pilar Solis-Hernandez
Maria Pilar Solis-Hernandez
PJPaula Jiménez
Paula Jiménez
LFLaura Faez-García
Laura Faez-García
CFCarlos Alvarez Fernandez
Carlos Alvarez Fernandez
QAQuionia Pérez Arnillas
Quionia Pérez Arnillas
JPJose Maria Vieitez De Prado
Jose Maria Vieitez De Prado
Background: Some patients with mCRC are still susceptible to continue with active therapy after progression to fluoropyrimidines, oxaliplatin, and irinotecan regimens due to their good performance status. Preclinical and clinical trials suggest that gemcitabine and fluoropyrimidines are synergic antimetabolites. Their major mechanism of action is to incorporate dFdCTP into DNA and to introduce FUTP into RNA, respectively, affecting their processing and function. This study aims to describe patients profile and response to gemcitabine-capecitabine (GemCap) in heavily pretreated mCRC, and so possible predictive factors for survival. Methods: Between June 2001 and July 2011, 119 evaluable patients pretreated with oxaliplatin and irinotecan regimens were enrolled: ECOG 0-1 97%, male 68%, median age 63yo, range: 36-79, rectum 57%, 3rd line: 61%. Patients received Gem 1000 mg/m2 d2 and Cap 1000 mg/m2BID x 7d q2w. Survival analysis was determined by Kaplan-Meier and log-rank test. Results: ORR and clinical benefit were: 5% and 36%. Median PFS and OS were 2.83m (0.43-35) and 6.53m (0.47m-10yrs in patient with complete response). Most frequent toxicities were anemia (22%), thrombocytopenia (10%), hand-foot syndrome (9%) and grade ≥3 were diarrhea in 5%. There were no treatment-related deaths. Predictive factors for PFS and OS are shown in Table. Statistic significance was registered in favor of clinical benefit achieved and for those who had not previously received monoclonal Abs, for SLP and OS respectively. Moreover, patients under 65yo tend to have a better survival. Conclusions: These data suggest GemCap is a tolerable regimen that achieves maintained responses for non selected heavily preated mCRC patients, especially in those reaching radiological clinical benefit, without previous use of monoclonal Abs and younger patients.

11 October 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MSMaria Pilar Solis-Hernandez
Maria Pilar Solis-Hernandez
LFL. Faez
L. Faez
DCD. Cantero
D. Cantero
ALA. Hernandez Lain
A. Hernandez Lain
PSPilar Sanchez-Gomez
Pilar Sanchez-Gomez
Juan-Manuel Sepúlveda SánchezJuan-Manuel Sepúlveda Sánchez
Juan-Manuel Sepúlveda Sánchez
Background High frequencies of TERT promoter mutations have been described in gliomas. This underlies telomere maintenance upregulating telomerases. The mutation rate is higher in glioblastomas (GBM). Methods Observational and retrospective analysis of 100 patients with different histological types of gliomas. TERT mutations were determined by RT-PCR in brain tumor samples obtained from paraffin-embedded tissue. Survival analysis was performed with Kaplan-Meier curves compared by Log-Rank test. Results There were included 52% GBM, oligodendrogliomas (OO) 12% and astrocytomas (AA) 29% each, and oligoastrocytomas (OA) 7%. The highest rate of TERT mutation was achieved in the OO group (66.7%) followed by GBM (55.8%) and AA (27.6%). From the 46% patients with TERT mutation: GBM 63%, OO and AA each 17.4%. Median relapse/progression free survival was 37, 33 and 7 months for AA, OO, OA and GBM respectively if wild type TERT, while if mutated 14, 20 and 8 months. TERT and ATRX seem to be mutually exclusive as there were only 2% coincidences.

6 December 2014 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
PFPaula Jimenez Fonseca
Paula Jimenez Fonseca
MSM. P. Solis
M. P. Solis
MGM. Garrido
M. Garrido
LFL. Faez
L. Faez
DRD. Rodriguez
D. Rodriguez
JVJ. M. Viéitez
J. M. Viéitez
In the published original article, Table 4, column “Frequency” contains some wrong terms. The correct table is given here.

18 September 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ARA. Revuelta
A. Revuelta
DRD. Rodríguez Rubí
D. Rodríguez Rubí
MLM.L. Sánchez Lorenzo
M.L. Sánchez Lorenzo
LEL. Ruiz Echeverria
L. Ruiz Echeverria
WLW. Li
W. Li
EEE. Esteban
E. Esteban
Background: Totally implantable central venous catheters are widely used in the management of patients (pts) with malignant diseases in order to facilitate drug delivery for the new therapeutic protocols. These are based on continuous administration and higher doses of chemotherapeutic agents with relative phlebitis problems and supportive treatment. Staff of our department, specially trained on the routinely implant of central venous accesses were in charge of the procedure. The technique was carried out under local anesthesia in a special suite of day hospital, under strict aseptic measures without fluoroscopic control. Methods: From Sep 94 to January 2017, 1665 devices (port-a-cath systems [PS]) were implanted in 1627 pts, with a median age of 50.5 yr (range 14-81), and median K.I. 70% (50-100), female 982/male 683. Venous access: right interior jugular 983, left subclavian 316, right subclavian 333, left interior jugular 33. A thorax X-ray was performed after each procedure and in 216 pts prophylactic antibiotics were given. Results: The venous access remained implanted a median of 438 days (1- +2210). Complications occurred in 266 placements (16%): Infections 116 (7%); deep venous thrombosis 66 (4%) obstruction 10 (0.6%); malpositioned 16 (2%); fractures/migration 28 (1.7%); pneumothorax 6 (0.32%); local skin necrosis 7 (0.6%). Five hundred and twenty devices were removed, three hundred and forty-seven (66%) after completing planned therapy and 173 (34%) due to complications [Infections (92), migration (22), malposition (12), venous thrombosis (26), obstruction (11) and skin necrosis (10)]. Cost-effectiveness of venous catheters in a non-surgical scenery compared to devices implanted by interventional vascular radiologists in operating room turned out to be 1000 euro cheaper for each device. Conclusions: Our experience suggests that implant of vascular access devices by medical oncologist in a non-surgical scenery has similar or even less complications and is more cost effective with regard to radiology suite and operating room placement procedures. Legal entity responsible for the study: Emilio Esteban, Oncología Médica, Hospital Universitario Central de Asturias. Funding: None